New malaria vaccine shows promise in first human trial in africa
NCT ID NCT06652737
First seen Feb 28, 2026 · Last updated May 01, 2026 · Updated 7 times
Summary
This study tested a new malaria vaccine (PfSPZ-LARC2) in 75 healthy adults and children in Burkina Faso. The vaccine uses genetically weakened malaria parasites that grow in the liver but cannot cause blood-stage infection, aiming to trigger strong immunity safely. The main goal was to check safety and whether the vaccine stays contained in the liver without causing malaria.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALARIA,FALCIPARUM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Groupe de Recherche Action en Santé (GRAS) / Unité de Recherche Clinique de Sabou
Ouagadougou, 06, Burkina Faso
Conditions
Explore the condition pages connected to this study.